Transposition and implementation of EU rare disease policy in Eastern Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 17, Issue 6, 2017, Pages 557-566

  Pejcic, Ana V ^a   Iskrov, Georgi ^b,c   Raycheva, Ralitsa ^b   Stefanov, Rumen ^b,c  

^a Michael)   (Serbia)

^b MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^c Institute of Rare Diseases   (Bulgaria)

Author keywords

EU; European reference networks; national plans; orphan drugs; Rare diseases; registries

Indexed keywords

ORPHAN DRUG;

BUDGET; DISEASE REGISTRY; DRUG COST; EUROPEAN UNION; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; ICD-10; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; NEWBORN SCREENING; RARE DISEASE; REIMBURSEMENT; REVIEW; SUPPORT GROUP; EASTERN EUROPE; MANAGEMENT; PRACTICE GUIDELINE;

EUROPE, EASTERN; EUROPEAN UNION; GUIDELINES AS TOPIC; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; POLICY MAKING; RARE DISEASES;

EID: 85032990300     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2017.1388741     Document Type: Review

References (85)

1. European Commission. Implementation report on the commission communication on rare diseases: Europe’s challenges and council recommendation of 8 June 2009 on an action in the field of rare diseases. Brussels. 2014. Available at https://ec.europa.eu/health/sites/health/files/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf
2. Commission Communication on the framework for action in the field of public health. COM (93) 559 final, 24 November 1993. [cited 2017 Sep29]. Available from: http://aei.pitt.edu/5792/1/5792.pdf
3. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). The Council of the European Union. Off J Eur Union. 2009;C 151:7–10.
4. Directive 2011/24/EU of the European parliament and of the council of 9 March 2011 on the application of patients’ rights in cross-border healthcare. The European Parliament and the Council of the European Union. Off J Eur Union. 2011;L 88:45–65.
5. Rodwell C, Aymé S, eds. 2014 Report on the state of the art of rare disease activities in Europe; 2014 Jul [cited 2017 Aug 27]. Available from: http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivities.pdf
6. Jakovljevic MB., Resource allocation strategies in southeastern European health policy. Eur J Health Econ. 2013;14(2):153–159.
7. European Commission Directorate–General for Health and Food Safety. National plans to combat rare diseases. [cited 2017 Apr24]. Available from: https://ec.europa.eu/health/rare_diseases/national_plans_en
8. Ministry of Health of the Republic of Serbia. Strategies; [cited 2017 Apr24]. Available from: http://zdravlje.gov.rs/showpage.php?id=138
9. Government of the Republic of Macedonia. 2009 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://challenges.mk/wp-content/uploads/2016/07/%D0%9F%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%D0%B0-%D0%B7%D0%B0-%D1%80%D0%B5%D1%82%D0%BA%D0%B8-%D0%B1%D0%BE%D0%BB%D0%B5%D1%81%D1%82%D0%B8-2009-%D0%B3%D0%BE%D0%B4%D0%B8%D0%BD%D0%B0.pdf
10. Government of the Republic of Macedonia. 2010 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://www.slvesnik.com.mk/Issues/D6AD7B35EF786A45BBDA08EA9BC7D776.pdf
11. Government of the Republic of Macedonia. 2011 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://www.slvesnik.com.mk/Issues/595CF4961E57714C93E86B782BFDF26D.pdf
12. Government of the Republic of Macedonia. 2012 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://healthrights.mk/pdf/Zdravstveni%20Rabotnici/Preventivni%20i%20kurativni%20programi%20na%20MZ/%D0%9F%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%D0%B0%20%D0%B7%D0%B0%20%D0%BB%D0%B5%D0%BA%D1%83%D0%B2%D0%B0%D1%9A%D0%B5%20%D0%BD%D0%B0%20%D1%80%D0%B5%D1%82%D0%BA%D0%B8%20%D0%B1%D0%BE%D0%BB%D0%B5%D1%81%D1%82%D0%B8%20%D0%B2%D0%BE%20%D0%A0%D0%9C%20%D0%B7%D0%B0%202012%20%D0%B3%D0%BE%D0%B4%D0%B8%D0%BD%D0%B0.pdf
13. Government of the Republic of Macedonia. 2013 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://zdravstvo.gov.mk/wp-content/uploads/2012/12/retki-bolesti-2013.pdf
14. Government of the Republic of Macedonia. 2014 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://www.fzo.org.mk/WBStorage/Files/16.%20Programa%20za%20lekuvanje%20na%20retki%20bolesti%20vo%20Republika%20Makedonija%20za%202014%20godina.pdf
15. Government of the Republic of Macedonia. 2015 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://healthrights.mk/pdf/Zdravstveni%20Rabotnici/Preventivni%20i%20kurativni%20programi%20na%20MZ/2015/%D0%9F%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%D0%B0%20%D0%B7%D0%B0%20%D0%BB%D0%B5%D0%BA%D1%83%D0%B2%D0%B0%D1%9A%D0%B5%20%D0%BD%D0%B0%20%D1%80%D0%B5%D1%82%D0%BA%D0%B8%20%D0%B1%D0%BE%D0%BB%D0%B5%D1%81%D1%82%D0%B8%20%D0%B2%D0%BE%20%D0%A0%D0%9C%20%D0%B7%D0%B0%202015%20%D0%B3%D0%BE%D0%B4%D0%B8%D0%BD%D0%B0.pdf
16. Government of the Republic of Macedonia. 2016 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://challenges.mk/wp-content/uploads/2013/04/Programa-za-lekuvanje-na-retki-bolesti-vo-R.M.-za-2016.pdf
17. Government of the Republic of Macedonia. 2017 Programme for treatment of rare diseases in the Republic of Macedonia. [cited 2017 Apr29]. Available from: http://www.fzo.org.mk/WBStorage/Files/PROGRAMA_ZA_LEKUVANE_NA_RETKI_BOLESTI_VO_RM_ZA_2017_GODINA.pdf
18. Ministry of Health of Federation of Bosnia and Herzegovina. Federation of Bosnia and Herzegovina’s strategy for rare diseases (2014-2020). [cited 2017 Apr29]. Available from: http://www.fmoh.gov.ba/images/federalno_ministarstvo_zdravstva/zakoni_i_strategije/strategije_i_politike/dokumenti/STRATEGIJA_RB_FBIH.pdf
19. Ministry of Health and Social Welfare of the Republic of Srpska. Programme for rare diseases in the Republic of Srpska (2015-2020). [cited 2017 Apr29]. Available from: http://www.vladars.net/sr-SP-Cyrl/Vlada/Ministarstva/MZSZ/Documents/%D0%9F%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%20%D0%B7%D0%B0%20%D1%80%D0%B8%D1%98%D0%B5%D1%82%D0%BA%D0%B5%20%D0%B1%D0%BE%D0%BB%D0%B5%D1%81%D1%82%D0%B8%20%D1%83%20%D0%A0%D0%B5%D0%BF%D1%83%D0%B1%D0%BB%D0%B8%D1%86%D0%B8%20%D0%A1%D1%80%D0%BF%D1%81%D0%BA%D0%BE%D1%98%202015_2020.pdf
20. Ministry of Health of Montenegro. National strategy for rare diseases in Montenegro 2013-2020. [cited 2017 Apr24]. Available from: http://www.mzdravlja.gov.me/ResourceManager/FileDownload.aspx?rid=122286&rType=2&file=Nacionalna%20strategija%20za%20rijetke%20bolesti.pdf
21. Ministry of Health of Albania. Strategic documents. [cited 2017 Apr 24]. Available from: http://www.shendetesia.gov.al/al/baza-ligjore/dokumenta-strategjike
22. European Commission Directorate–General for Health and Food Safety. European Reference Networks. [cited 2017 Apr24]. Available from: https://ec.europa.eu/health/ern/policy_en
23. Burgard P, Cornel M, Di Filippo F, et al. Short Executive Summary of the Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA countries. 2011; [cited 2017 Apr24]. Available from: http://ec.europa.eu/chafea/documents/news/Summary_20120110.pdf
24. Rare Disease Registries in Europe (Orphanet Report Series). 2017 May. [cited 2017 Apr 24]. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf
25. European Commission Directorate–General for Health and Food Safety. Regional conference on Rare Diseases. 2014; [cited 2017 Apr24]. Available from: http://ec.europa.eu/chafea/documents/health/prague-rd-programme_en.pdf
26. Ministry of Health. Ordinance № 16 of 30 July 2014 on the terms and conditions for registration of rare diseases and on the centres of expertise and reference networks for rare diseases. State Gazette 67 of 12 August 2014. [cited 2017 Apr24]. Available from: https://www.mh.government.bg/media/filer_public/2015/04/16/naredba16-ot-30-07-2014g-registrirane-redki-zaboliavania.pdf
27. Cisárik F, Baráková A. The creation of the national registry of rare diseases in the Slovak Republic. Acta Fac Pharm Univ Comen. 2014;61(1):9–15.
28. Orphanet: About Orphanet. [cited 2017 Apr24]. Available from: http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanet.php?lng=EN
29. National Health Insurance Fund of Hungary. [cited 2017 Apr29]. Available from: http://www.neak.gov.hu/felso_menu/szakmai_oldalak/gyogyszer_segedeszkoz_gyogyfurdo_tamogatas/egeszsegugyi_vallalkozasoknak/gyartok_forgalomba_hozok/dipc.html
30. State Institute for Drug Control of the Czech Republic. [cited 2017 Apr29]. Available from: http://www.sukl.eu/sukl/list-of-reimbursed-medicinal-products
31. National Health Insurance Fund of the Republic of Serbia. [cited 2017 Apr29]. Available from: http://www.rfzo.rs/index.php/osiguranalica/lekovi-info/lekovi-actual
32. National Health Insurance Fund of Montenegro. [cited 2017 Apr29]. Available from: http://fzocg.me/#sadrzaj(23)
33. National Health Insurance House of Romania. [cited 2017 Apr29]. Available from: http://www.cnas.ro/category/lista-medicamentelor.html
34. National Council on Prices and Reimbursement of Medicinal Products of Bulgaria. [cited 2017 Apr 29]. Available from: http://portal.ncpr.bg/registers/pages/register/list-medicament.xhtml
35. Croatian Health Insurance Fund. [cited 2017 Apr29]. Available from: http://www.hzzo.hr/zdravstveni-sustav-rh/trazilica-za-lijekove-s-vazecih-lista/
36. National Organization for Medicines of Greece. [cited 2017 Apr29]. Available from: http://www.eof.gr/web/guest/announcementsgeneral?p_p_id=62_INSTANCE_SK2n&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&_62_INSTANCE_SK2n_struts_action=%2Fjournal_articles%2Fview&_62_INSTANCE_SK2n_groupId=12225&_62_INSTANCE_SK2n_articleId=1850515&_62_INSTANCE_SK2n_version=1.0
37. Health Insurance Institute of Slovenia. [cited 2017 Apr29]. Available from: http://www.zzzs.si/zzzs/info/egradiva.nsf/o/A1CDE0432EC8F258C12579F7003B6AF2?OpenDocument
38. National Health Insurance Fund of Macedonia. [cited 2017 Apr29]. Available from: http://www.fzo.org.mk/default.asp?ItemID=8F44F37EC3802A43968F825481D42074
39. Health Insurance Fund of the Republic of Srpska. [cited 2017 Apr29]. Available from: https://www.zdravstvo-srpske.org/liste-lijekova.html
40. Ministry of Health of Sarajevo Canton, Federation of Bosnia and Herzegovina. [cited 2017 Apr29]. Available from: http://mz.ks.gov.ba/propisi
41. Albanian Health Insurance Institute. [cited 2017 Apr29]. Available from: http://www.fsdksh.com.al/lista-e-barnave
42. Ministry of Health of the Slovak Republic. [cited 2017 Apr29]. Available from: http://www.health.gov.sk/?zoznam-kategorizovanych-liekov
43. Ministry of Health of Poland. [cited 2017 Apr29]. Available from: http://www.mz.gov.pl/leki/refundacja/lista-lekow-refundowanych-obwieszczenia-ministra-zdrowia/
44. IRDiRC. IRDiRC Members. [cited 2017 Apr24]. Available from: http://www.irdirc.org/about-us/members/
45. ERA-Net for Research Programmes on Rare Diseases. Partners. [cited 2017 Apr24]. Available from: http://www.erare.eu/Partners
46. EURORDIS. Membership of EURORDIS. [cited 2017 Apr24]. Available from: http://www.eurordis.org/membership
47. European Commission Directorate–General for Health and Food Safety. Commission expert group on rare diseases. [cited 2017 Apr24]. Available from: https://ec.europa.eu/health/rare_diseases/expert_group_en
48. RD-ACTION. About us. [cited 2017 Apr24]. Available from: http://www.rd-action.eu/about-us/
49. Posada M, Carroquino MJ, Hens Pérez M, EUROPLAN Working group on indicators. Selecting indicators to evaluate the achievements of RD initiatives. 2011 [cited 2017 Aug27]. Available from: http://www.europlanproject.eu/_europlanproject/Resources/docs/2008-2011_3.EuroplanIndicators.pdf
50. EUCERD Recommendations on Core Indicators for Rare Disease National Plans/Strategies; 2013 Jun 6 [cited 2017 Aug 27]. Available from: http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_Indicators_adopted.pdf
51. EUCERD Report: Health Indicators for Rare Diseases: Conceptual framework for the use of health indicators for monitoring quality of care; Sep 2011 [cited 2017 Sep 29]. Available from: http://www.eucerd.eu/?post_type=document&p=1353
52. Ministry of Health of Poland. National plan on rare diseases. [cited 2017 Aug 27]. Available from: http://www.mz.gov.pl/leczenie/choroby-rzadkie/narodowy-plan-dla-chorob-rzadkich/
53. Romanian EUROPLAN National Conference Final Report; 2013 [cited 2017 Aug27]. Available from: http://www.eucerd.eu/upload/file/WP4finalreport_romania.pdf
54. Ministry of Health of Romania. National Health Strategy 2014-2020. [cited 2017 Aug27]. Available from: http://www.ms.ro/strategia-nationala-de-sanatate-2014-2020/
55. Popescu LG. Analysis of national health strategy 2014-2020. Theor Appl Econ. 2015;22(4):177–188.
56. Petrusic T, Jakovljevic M. Budget impact of publicly reimbursed prescription medicines in the Republic of Srpska. Front Public Health. 2015;3:213.
57. Budget of the Ministry of Health of the Republic of Serbia for 2016. [cited 2017 Aug27]. Available from: http://www.zdravlje.gov.rs/downloads/2016/April/April2016Budzet2016.pdf
58. Jakovljevic MB, Djordjevic N, Jurisevic M, et al. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):521–530.
59. Law on Health Insurance. Official Gazette of the Republic of Montenegro 006/16 and 002/17. [cited 2017 Aug27]. Available from: http://www.mzdravlja.gov.me/ResourceManager/FileDownload.aspx?rid=229310&rType=2&file=Zakon%20o%20zdravstvenom%20osiguranju.pdf
60. National alliance for rare diseases of Montenegro. [cited 2017 Aug27]. Available from: http://rijetkebolesti.com/
61. National alliance for rare diseases of the Republic of Srpska, Banja Luka. [cited 2017 Aug27]. Available from: http://www.akta.ba/bs/firme/savez-za-rijetke-bolesti-republike-srpske/266046
62. Jakovljevic MB, Vukovic M, Fontanesi J. Life expectancy and health expenditure evolution in eastern Europe-DiD and DEA analysis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):537–546.
63. Taruscio D, Vittozzi L, Stefanov R. National plans and strategies on rare diseases in Europe. Adv Exp Med Biol. 2010;686:475–491.
64. Stefanov R, Taruscio D. Rare diseases and orphan drugs in eastern European countries. Ital J Public Health. 2009;6(4):289–293.
65. Ray-Coquard I, Pujade Lauraine E, Le Cesne A, et al. Improving treatment results with reference centres for rare cancers: where do we stand? Eur J Cancer. 2017;77:90–98.
66. Laimer M, Pohla-Gubo G, Diem A, et al. Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network: example of a centre of expertise implemented in a European reference network to face the burden of a rare disease. Wien Klin Wochenschr. 2017;129(1–2):1–7.
67. Evangelista T, Hedley V, Atalaia A, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis. 2016;11:17.
68. Taruscio D, Gentile AE, Evangelista T, et al. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD recommendations. Blood Transfus. 2014;12(Suppl 3):s621–s625.
69. Taruscio D, Vittozzi L, Choquet R, et al. National Registries of Rare Diseases in Europe: an overview of the current situation and experiences. Public Health Genomics. 2015;18(1):20–25.
70. Rodger S, Lochmüller H, Tassoni A, et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8:171.
71. Zoni AC, Domínguez Berjón MF, Barceló E, et al. Identifying data sources for a national population-based registry: the experience of the Spanish Rare Diseases Registry. Public Health. 2015;129(3):271–275.
72. Cavero-Carbonell C, Gras-Colomer E, Guaita-Calatrava R, et al. Consensus on the criteria needed for creating a rare-disease patient registry. A Delphi study. J Public Health Oxf Engl. 2016;38(2):e178–e186.
73. Zelei T, Molnár MJ, Szegedi M, et al. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet J Rare Dis. 2016;11(1):72.
74. Iskrov G, Jessop E, Miteva-Katrandzhieva T, et al. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria. Georgian Med News. 2015;242:46–53.
75. Iskrov G, Stefanov R. Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in Bulgaria. Front Public Health. 2015;3:64.
76. Kolasa K, Kalo Z, Hornby E. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):145–155.
77. Kaló Z, Gheorghe A, Huic M, et al. HTA implementation roadmap in central and eastern European countries. Health Econ. 2016;25(Suppl 1):179–192.
78. Jakovljevic MM, Arsenijevic J, Pavlova M, et al. Within the triangle of healthcare legacies: comparing the performance of south-eastern European health systems. J Med Econ. 2017;20(5):483–492.
79. Espín J, Rovira J, Calleja A, et al. How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe. Policy Brief. 2016;21. [cited 2017 Aug27]. Available from https://www.eu2017.mt/Documents/Programmes/PB21.pdf
80. Rath A, Olry A, Dhombres F, et al. Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat. 2012;33(5):803–808.
81. Maiella S, Rath A, Angin C, et al. [Orphanet and its consortium: where to find expert-validated information on rare diseases]. Rev Neurol (Paris). 2013;169(Suppl 1):S3–S8.
82. Andersen T, Le Cam Y, Weinman A. European Reference Networks for Rare Diseases: the vision of patients. Blood Transfus. 2014;12(Suppl 3):s626–s627.
83. Jakovljevic MM, Ogura S. Health economics at the crossroads of centuries - from the past to the future. Front Public Health. 2016;4:115.
84. Jakovljevic M, Pejcic AV. Growth of global publishing output of health economics in the twenty-first century: a bibliographic insight. Front Public Health. 2017;5:211.
85. Hollak CEM, Biegstraaten M, Baumgartner MR, et al. Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks. Orphanet J Rare Dis. 2016;11:7.